Guidelines

Table 2. Recommended Intraoral Photobiomodulation Therapy Protocols for the Prevention of Oral Mucositis

Document Overview

Design and created by Guideline Central in participation with the Multinational Association of Supportive Care in Cancer.

Management of Mucositis Secondary to Cancer Therapy

Multinational Association of Supportive Care in Cancer

Publication Date: Jun 30, 2020

Page Last Updated: May 5, 2026

Table 2. Recommended Intraoral Photobiomodulation Therapy Protocols for the Prevention of Oral Mucositis

Cancer Treatment Modality	Wavelength, nm	Power Density (Irradiance), mW/cm²	Time per Spot, s	Energy Density (Fluence), J/cm²	Spot Size, cm²	No. of Sites	Duration
HSCT	632.8	31.25	40	1.0	0.8	18	From the d after cessation of conditioning for 5 d
HSCT	650	1000^b	2	2.0	0.04	54-70	From the first d of conditioning to d + 2 post-HSCT (for 7-13 d)
RT	632.8	24	125	3.0	1.00	12	Entire RT course
RT-CT	660	417^b	10	4.2	0.24	72	Entire RT course
RT-CT	660	625^b	10	6.2	0.04	69	Entire RT course

Level of Evidence

Document Overview

Document Title: Management of Mucositis Secondary to Cancer Therapy

Authoring Society: Multinational Association of Supportive Care in Cancer

Document Publication Date: Jun 30, 2020

Page Last Reviewed/Updated: May 5, 2026

Document Type: Guideline

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.33100

Source Citation: Elad, S, Cheng, KKF, Lalla, RV, Yarom, N, Hong, C, Logan, R M., Bowen, J, Gibson, R, Saunders, DP, Zadik, Y, Ariyawardana, A, Correa, ME, Ranna, V, Bossi, P; for the Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020: 126: 4423– 4431. https://doi.org/10.1002/cncr.33100

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Scope: Management

Diseases/Conditions (MeSH)

D052016 - Mucositis

Keywords: Mucositis, Oral mucositis, erythema, secondary cancer therapy

Inclusion Criteria: Female, Male, Adult

Health Care Settings: Ambulatory, Hospital, Long Term Care

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant, Social Worker

Recommendation Development Processes & Methodology

Supplemental Methodology Resource: Data Supplement

Number of Source Documents: 271

Literature Search Start Date: Friday, December 31, 2010

Literature Search End Date: Wednesday, June 29, 2016

Includes peer/external review process?: Yes

Includes public comment process?: No

Methodologist involvement?: Yes

Patient involvement?: No

Includes multi-disciplinary group?: Yes

Includes systematic review?: Yes

Grades quality of strength of evidence?: Yes

Grades quality of strength of recommendation?: Yes

Discloses funding source?: Yes

Discloses conflicts of interest?: Yes

Includes benefits/harms analysis with recommendations?: No

Grade	Definition
Level of Evidence
Level I	Based on good and consistent scientific evidence.
Level II	Based on limited or inconsistent scientific evidence.
Level III	Based primarily on consensus and expert opinion.

Management of Mucositis Secondary to Cancer Therapy

Guidelines

Basic Oral Care

Anti-inflammatory Agents

Photobiomodulation

Cryotherapy

Antimicrobials, coating agents, anesthetics, and analgesics

Growth factors and cytokines

Natural and miscellaneous

Gastrointestinal Mucositis

Table 2. Recommended Intraoral Photobiomodulation Therapy Protocols for the Prevention of Oral Mucositis

Level of Evidence

Document Overview

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Recommendation Development Processes & Methodology